Trial Profile
Discontinuation risk and health care resource utilization between the vitamin K antagonists (VKAs) and the novel oral anticoagulants (NOACs) in newly treated patients with non-valvular atrial fibrillation (NVAF)
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 23 Oct 2017
Price :
$35
*
At a glance
- Drugs Apixaban (Primary) ; Dabigatran etexilate (Primary) ; Rivaroxaban (Primary) ; Vitamin K antagonists
- Indications Embolism and thrombosis; Stroke
- Focus Therapeutic Use
- 08 Nov 2017 Results presented at the 20th Annual European Congress of the International Society for Pharmacoeconomics and Outcomes Research
- 23 Oct 2017 New trial record